Drugs / HRS-1893
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07033455 | Jun → Sep 2025 | hypertrophic cardiomyopathy | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07656779 | Jun → Jul 2026 overdue | cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07272330 | Dec 2025 → Mar 2026 | cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06775834 | Feb → Jul 2025 | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06354556 | Apr → May 2024 | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05879523 | Jun 2023 → Mar 2024 | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07269717 | Mar 2026 → Mar 2027 expected | diastolic heart failure | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07021963 | Jul 2025 → Dec 2027 expected | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06816251 | Feb → Aug 2025 overdue | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06516068 | Aug → Nov 2024 overdue | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07021976 | Aug 2025 → Sep 2026 expected | hypertrophic cardiomyopathy | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1893 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07021976 ↗ |
| Action | Inhibit | “HRS-1893, a cardiac myosin inhibitor” PMID 42160017 ↗ May 2026 |
| Route | Subcutaneous | “subcutaneous, single dose, multiple doses” NCT05879523 ↗ |